Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements - Additional Information (Detail)

v3.21.1
Collaboration and License Agreements - Additional Information (Detail) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Janssen Pharmaceutical NV [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Accrued royalties $ 0   $ 0
Janssen Pharmaceutical NV [Member] | Maximum [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Percentage of royalty on net sales 8.00%    
DiaTex, Inc. [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Royalty payment $ 0 $ 0  
Development payment $ 0 $ 0